TITLE:
Unique Clinical Features of Curaderm when Treating Skin Cancers
AUTHORS:
Tania Robyn Chase, Kai Elliot Cham, Bill Elliot Cham
KEYWORDS:
Curaderm, Skin Cancer, Basal Cell Carcinoma, BEC, Glycoalkaloids, Conventional Treatments
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.15 No.1,
January
17,
2024
ABSTRACT: Basal
cell carcinoma is the most common form of skin cancer and the most frequently
occurring form of all cancers. Conventional treatments to remove or destroy
basal cell carcinoma are indiscriminate and also remove or destroy normal skin cells resulting in compromised cosmetic
outcomes. Consequences of these treatments include body-image issues,
anxiety, post-traumatic stress disorder, depression, and poorer quality of
social and family life. A progressive topical cream formulation, Curaderm,
containing the natural BEC glycoalkaloids, have shown to have advantages over
conventional treatments. However, comprehensive clinical features of the skin
cancer lesions during treatment with Curaderm have to date not been reported.
This report shows that using unpublished data from a large number of patients
with varying sizes, types and locations of basal cell carcinomas when treated
with Curaderm in a phase 3 trial, an initial increase in size of the lesions
occur, followed by a reverse course, leading to complete removal of the skin
cancer. The specificity and mode of action of Curaderm explains the superior
cosmetic outcomes when compared with conventional therapies.